Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Advances in mesothelioma treatment

Dean Fennell • 26 May 2020
ASCO 2020
Lung Cancer Mesothelioma Rucaparib
MiST

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, discusses advances in the treatment of mesothelioma, including the results of the MiST1 study (NCT03654833) which resulted in greater than 50% disease control in BAP1/BRCA1 deficient relapsed malignant mesothelioma treated with rucaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Dean Fennell

1:14
ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell • 27 Apr 2023
3:34
Role of immunotherapy in the management of mesothelioma
Dean Fennell • 31 Mar 2023
6:43
Personalized medicine in mesothelioma
Dean Fennell • 31 Mar 2023
1:54
Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma
Dean Fennell • 21 May 2021

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals